References
- Krishna MT, Mahesh PA, Vedanthan PK, Mehta V, Moitra S, Etal CD. The global asthma report 2018 [online]. Available at: http://www.globalasthmareport.org/resources/global_asthma_report_2018.pdf. Accessed January 22, 2020.
- Singh S, Sharma BB, Salvi S, Chhatwal J, Jain KC, Kumar L, Joshi MK, Pandramajal SB, Awasthi S, Bhave S, et al. Allergic rhinitis, rhinoconjunctivitis, and eczema: prevalence and associated factors in children. Clin Respir J. 2018;12(2):547–556. doi:https://doi.org/10.1111/crj.12561.
- Masoli M, Fabian D, Holt S, Beasley R; on behalf of GINA. Global burden of asthma: developed for the global initiative for asthma. Available at: http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf. Accessed September 3, 2015.
- Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol. 2007;119(6):1454–1461. doi:https://doi.org/10.1016/j.jaci.2007.03.022.
- Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med. 2006;100(3):434–450. doi:https://doi.org/10.1016/j.rmed.2005.06.012.
- Thompson PJ, Salvi S, Lin J, Cho YJ, Eng P, Abdul Manap R, Boonsawat W, Hsu J-Y, Faruqi RA, Moreno-Cantu JJ. Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. Respirology. 2013;18(6):957–967. doi:https://doi.org/10.1111/resp.12137.
- Chisholm A, Price DB, Pinnock H, Tan TL, Roa C, Cho S-H, David-Wang A, Wong G, van der Molen T, Ryan D, et al. Personalising care of adults with asthma from Asia: a modified e-Delphi consensus study to inform management tailored to attitude and control profiles. NPJ Prim Care Respir Med. 2017;27:17002. doi:https://doi.org/10.1038/npjpcrm.2017.2.
- Bikov A, Oğuzülgen IK, Baiardini I, Contoli M, Emelyanov A, Fassio O, Ivancevich JC, Kaidashev I, Kowal K, Labor M, et al. Beliefs and preferences regarding biological treatments for severe asthma. World Allergy Organ J. 2020;13(7):100441. doi:https://doi.org/10.1016/j.waojou.2020.100441.
- Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, etal. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50:1701782. doi:https://doi.org/10.1183/13993003.01782-2017.
- Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, Luskin AT, Solari PG. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2. doi:https://doi.org/10.1016/j.jaci.2016.08.054.
- Rajesh V, Augustine J, Divya R, Cleetus M. Inhaled formoterol-fluticasone single inhaler therapy in asthma: real-world efficacy, budget impact, and potential to improve adherence. Can Respir J. 2020;2020:8631316. doi:https://doi.org/10.1155/2020/8631316.
- Venkitakrishnan R, Thomas PK, Bansal A, Ghosh I, Augustine Dtcd Dnb J, Divya R, Cleetus M. Fluticasone/formoterol compared with other ICS/LABAs in asthma: a systematic review. J Asthma. 2021. doi:https://doi.org/10.1080/02770903.2021.1900864.
- Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1–342. doi:https://doi.org/10.3310/hta17520.
- Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. doi:https://doi.org/10.1016/j.jaip.2017.02.002.
- Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M, Kianifard F, Ortiz B, Haselkorn T, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444. doi:https://doi.org/10.1016/j.jaci.2017.03.002.
- Divya R, Venkitakrishnan R, Augustine J, Cleetus M. Efficacy of omalizumab therapy in an asthmatic with low IgE. Case Rep Pulmonol. 2020;2020:8898454. doi:https://doi.org/10.1155/2020/8898454.
- Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, Annesi-Maesano I, Anto JM, Bachert C, Baena-Cagnani CE, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J. 2014;44(2):304–323. doi:https://doi.org/10.1183/09031936.00014614.
- Solèr M, Matz J, Townley R, Buhl R, O’brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. EurRespir J. 2001;18(2):254–261. doi:https://doi.org/10.1183/09031936.01.00092101.
- Vignola AM, Humbert M, Bousquet J, Boulet L-P, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–717. doi:https://doi.org/10.1111/j.1398-9995.2004.00550.x.
- Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, Molimard M, Abenhaim L. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143(2):398–405. doi:https://doi.org/10.1378/chest.12-1372.
- Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103(11):1725–1731. doi:https://doi.org/10.1016/j.rmed.2009.05.002.
- Caminati M, Senna G, Stefanizzi G, Bellamoli R, Longhi S, Chieco-Bianchi F, Guarnieri G, Tognella S, Olivieri M, Micheletto C, et al. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med. 2016;16(1):128. doi:https://doi.org/10.1186/s12890-016-0290-5.
- Campisi R, Crimi C, Intravaia R, Strano S, Noto A, Foschino MP, Valenti G, Viviano V, Pelaia C, Ricciardi L, et al. Adherence to omalizumab: a multicenter “real-world” study. World Allergy Organ J. (2)2020;13:100103. doi:https://doi.org/10.1016/j.waojou.2020.100103.
- Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017;124:36–43. doi:https://doi.org/10.1016/j.rmed.2017.01.008.
- Molimard M, Mala L, Bourdeix I, Gros VL. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014;108(4):571–576. doi:https://doi.org/10.1016/j.rmed.2014.02.003.